Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    5 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the clinical trial study related to the efficacy and safety of efprezimod alfa in COVID-19 treatment for hospitalized adult participants receiving oxygen support.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:56.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals diagnosed with severe or critical COVID-19 and confirmed SARS-CoV-2 infection, along with other specific health conditions and exclusions.
    Difference
    15%
    Check dated 2024-05-22T20:56:02.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:44:03.000Z thumbnail image

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.